Retrospective research from more than a decade ago demonstrated the potential benefit, but it hadn't been confirmed in a ...

In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo ...

The firm said it found its antibody-drug conjugate payload had activity as both a monotherapy and in combination with androgen receptor inhibitors.

The approval follows the CHMP's reversal of a previous decision not to recommend the drug, instead recommending it with certain restrictions.

The firm commenced a $200 million underwritten public offering, secured $125 million in non-dilutive funding, and refinanced $50 million in debt.

In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.

The approval includes patients whose disease progressed after treatment with endocrine therapy, which can cause ESR1 mutations.

The agency held a meeting to gather drugmakers' perspectives as it considers a draft guidance on how previously generated ...

Patients on Enhertu and Perjeta lived more than three years without disease progression compared to just over two years on Perjeta, Herceptin, and chemo.

The firm has licensed Solid's AAV-SLB101 capsid and plans to fund preclinical development with a potential $1.1 million investment from the Jain Foundation.

Researchers still see potential for the TIL therapy to benefit patients if combined with other immunotherapies, like checkpoint inhibitors.

The company submitted data showing A400's efficacy in patients with advanced RET fusion-positive NSCLC in first- or later-line treatment.